Frankfurt
24.07.26 | 15:25
0,495 Euro
+3,34 % +0,016
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.07. | Arch Biopartners Inc: Arch Biopartners hires lab for IL-32 kidney program | 1 | Stockwatch | ||
| 17.07. | Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program | 1 | GlobeNewswire (USA) | ||
| 04.06. | Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans | 1 | GlobeNewswire (USA) | ||
| 25.05. | XFRA NEW INSTRUMENTS AVAILABLE ON 25.05.2026 | 607 | Xetra Newsboard | The following instruments on XETRA do have their first trading 25.05.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.05.2026
Aktien
1 GRS148003015 Ideal Holdings S.A.
2... ► Artikel lesen | |
| ARCH BIOPARTNERS Aktie jetzt für 0€ handeln | |||||
| 22.05. | Arch Biopartners Inc: Arch Biopartners notes patient dosing in phase II trial | 1 | Stockwatch | ||
| 22.05. | Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial | 1 | GlobeNewswire (USA) | ||
| 30.04. | Arch Biopartners Inc: Arch Biopartners talks patient recruitment at RCH | 1 | Stockwatch | ||
| 11.04. | Arch Biopartners Inc: Arch Biopartners one-million-share private placement | 1 | Stockwatch | ||
| 02.04. | Arch Biopartners Inc: Arch Biopartners closes $600,000 private placement | 2 | Stockwatch | ||
| 02.04. | Arch Biopartners Closes Non-Brokered Private Placement | 1 | GlobeNewswire (USA) | ||
| 30.03. | Arch Biopartners Inc: Arch Biopartners arranges $600,000 private placement | 2 | Stockwatch | ||
| 30.03. | Arch Biopartners Arranges Non-Brokered Private Placement | 3 | GlobeNewswire (USA) | ||
| 25.03. | Arch Biopartners Inc: Arch, Royal Columbian enter clinical trial deal | 1 | Stockwatch | ||
| 24.03. | Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial | 2 | GlobeNewswire (USA) | ||
| 20.03. | Arch Biopartners Inc: Arch Biopartners begins dosing at 3rd CS-AKI trial site | 1 | Stockwatch | ||
| 20.03. | Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide | 1 | GlobeNewswire (USA) | ||
| 09.02. | Arch Biopartners Inc: Archlinks IL-32 to diabetic kidney inflammation | 1 | Stockwatch | ||
| 09.02. | Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease | 1 | GlobeNewswire (USA) | ||
| 05.11.25 | Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia | 249 | GlobeNewswire (Europe) | TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Research Ethics Board ("REB")... ► Artikel lesen | |
| 17.09.25 | Arch Biopartners: Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD) | 194 | GlobeNewswire (Europe) | Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly implicated... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,335 | -0,66 % | AKTIEN IM FOKUS 2: Danaher enttäuscht Anleger - Auch Sartorius-Kurs leidet | (neu: Kurse mit Danaher im offiziellen Handel, Analystenstimmen) FRANKFURT/NEW YORK (dpa-AFX) - Der Quartalsbericht von Danaher hat im Diagnostikbereich am Dienstag international eine Welle der Enttäuschung... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,680 | +0,15 % | Summit Therapeutics Flags Going Concern Risk Over Cash Needs | ||
| TARSUS PHARMACEUTICALS | 58,66 | 0,00 % | Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 | ||
| PRAXIS PRECISION MEDICINES | 324,95 | -0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,430 | -0,04 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,26 | -0,01 % | Apogee Therapeutics Aktie erreicht Rekordhoch von 134,34 USD | ||
| DISC MEDICINE | 74,12 | 0,00 % | Disc Medicine Inc: Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria | Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 52,95 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,740 | -0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ERASCA | 19,110 | 0,00 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,690 | 0,00 % | Vir Biotechnology: Abgang des Finanzchefs schickt Aktie auf Talfahrt | ||
| TANGO THERAPEUTICS | 26,630 | 0,00 % | How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% | ||
| EDGEWISE THERAPEUTICS | 40,790 | -0,12 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 45,700 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis | WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 21,860 | +0,97 % | Scribe Therapeutics Inc.: Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering | ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics") (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR... ► Artikel lesen |
Das Unternehmen ARCH BIOPARTNERS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,495 Euro und damit +3,34 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCH BIOPARTNERS INC finden Sie auf Wallstreet Online.